Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance [clinicaltrials:NCT00137657]

Bio2RDF uri

Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance [clinicaltrials:NCT00137657]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00137657

Bio2RDF identifier

NCT00137657

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00137657

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00137657

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:4c3cb4f1b6774aae040152e2cdb4237b

brief summary [clinicaltrials_vocabulary:brief-summary]

At least three studies ...... eiving CTX daily prophylaxis.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:9068570e9a9cd32de143a62fb63556ff]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:b0df437c3e133d3bb2d83c048f45fdd7]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:c0fe0c4b2b34b031aad93bf7d53263a9]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:0b0210edc4a9f500a902efdb6019c148]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:1a661e180fea87be446ba2bd744e10f7]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:1adb1fac40b15fdeff32d3e9a1eb4e41]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:4f9e98c0ef08cc0ebf4f12a4cd9b75a0]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:a58d3a2e6e1b3f601418620303887107]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:abe5d10c035ceb02be4d07f6088c5c8f]

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX [clinicaltrials_resource:d71060710f739d188eb985ca75a37377]

collaborator [clinicaltrials_vocabulary:collaborator]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

completion date [clinicaltrials_vocabulary:completion-date]

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

We conducted this study ...... lates, and commensal E. coli.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00137657 [clinicaltrials_resource:eebb91035c998a33a40cbf5a1d082f36]

enrollment [clinicaltrials_vocabulary:enrollment]

1.478

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Cotrimoxazole (trimethoprim sulfamethoxazole) [clinicaltrials_resource:6eff956b6729a8e8385e9c0548fecb15]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Sulfamethoxazole [clinicaltrials_resource:01b2c823690f30d37206de1741ea48f3]

Folic Acid Antagonists [clinicaltrials_resource:498225a4efee41150e5195e29b25dd54]

Trimethoprim [clinicaltrials_resource:893a87beeb73a36501b1090cf24191a3]

Trimethoprim-Sulfamethoxazole Combination [clinicaltrials_resource:a45af3c11c505503f3c043d1f35fcd47]

keyword [clinicaltrials_vocabulary:keyword]

Africa

http://www.w3.org/2001/XMLSchema#string

E. Coli

http://www.w3.org/2001/XMLSchema#string

East Africa

http://www.w3.org/2001/XMLSchema#string

HIV

http://www.w3.org/2001/XMLSchema#string

Kenya

http://www.w3.org/2001/XMLSchema#string

S. pneumoniae

http://www.w3.org/2001/XMLSchema#string

antifolate

http://www.w3.org/2001/XMLSchema#string

drug resistance

http://www.w3.org/2001/XMLSchema#string

malaria

http://www.w3.org/2001/XMLSchema#string

opportunistic infections

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2005-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

location [clinicaltrials_vocabulary:location]

CDC KEMRI Research Institute [clinicaltrials_resource:9e517cebe0f6598f9df608c0f73f01b2]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00137657

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

An Evaluation of the Impact of ...... eumoniae, and Escherichia Coli

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CDC-NCID-3354

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Mary J Hamel, M.D. [clinicaltrials_resource:9a10badc75c33fe9fd315c40157386e4]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:15a952dd0198445f4ddd5909936bc0e7]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

secondary id [clinicaltrials_vocabulary:secondary-id]

UR6/CCU018970-02-2

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

start date [clinicaltrials_vocabulary:start-date]

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00137657 study design [clinicaltrials_resource:418a3a47d8679c3e309a0b3b434204ca]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00137657

verification date [clinicaltrials_vocabulary:verification-date]

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00137657

http://www.w3.org/2001/XMLSchema#string

title

Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Impact of Cotrimoxazole Prophy ...... e [clinicaltrials:NCT00137657]

@en